Liquidia Falls as Patent Ruling Overhang Continues

Liquidia Corporation (LQDA) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued pressure from Liquidia’s Sept. 30 legal setback tied to YUTREPIA, its key commercial product. Investors appear to be weighing the risk that the ruling could force label changes for the PH-ILD use or lead to broader limits on product availability, which would materially affect the company’s revenue outlook.

Details:

Liquidia said a federal court found two asserted claims of the ‘327 patent valid and infringed in connection with YUTREPIA’s use in PH-ILD patients.

The company said both sides were directed to submit a proposed judgment within one week, leaving the market focused on potential remedies rather than a fully resolved outcome.

Liquidia said it plans to submit a supplement to remove PH-ILD from YUTREPIA’s label, underscoring that the disputed indication is now under pressure.

YUTREPIA is central to the business: Liquidia’s second-quarter results showed net product sales of about $170.4 million, helping explain why legal uncertainty around the product is weighing on the stock.

Sources:

Liquidia press release, SEC filing, Liquidia earnings release

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LQDA Insider Trading Activity

$LQDA insiders have traded $LQDA stock on the open market 119 times in the past 6 months. Of those trades, 1 have been purchases and 118 have been sales.

Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:

STEPHEN M BLOCH has made 0 purchases and 44 sales selling 1,687,458 shares for an estimated $116,128,836.
ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 21 sales selling 486,565 shares for an estimated $24,914,862.
MICHAEL KASETA (CFO and COO) has made 0 purchases and 9 sales selling 339,388 shares for an estimated $14,243,260.
PAUL B MANNING has made 0 purchases and 5 sales selling 200,000 shares for an estimated $12,782,058.
RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 5 sales selling 98,680 shares for an estimated $7,035,793.
JASON ADAIR (Chief Business Officer) has made 0 purchases and 7 sales selling 90,171 shares for an estimated $6,018,528.
KATHERINE RIELLY-GAUVIN has made 0 purchases and 2 sales selling 55,182 shares for an estimated $4,087,434.
RAMAN SINGH has made 0 purchases and 3 sales selling 46,986 shares for an estimated $2,952,888.
SARAH KREPP (Chief Human Resource Officer) has made 0 purchases and 6 sales selling 37,575 shares for an estimated $2,504,305.
RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 3 sales selling 28,430 shares for an estimated $1,579,287.
SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 4 sales selling 20,086 shares for an estimated $1,086,543.
DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 5 sales selling 17,279 shares for an estimated $1,039,054.
PARTNERS LP CALIGAN has made 1 purchase buying 5,300 shares for an estimated $317,894 and 1 sale selling 5,300 shares for an estimated $317,894.
SANJEEV KHINDRI (Chief Development Officer) has made 0 purchases and 3 sales selling 5,319 shares for an estimated $355,351.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$LQDA Hedge Fund Activity

We have seen 220 institutional investors add shares of $LQDA stock to their portfolio, and 105 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 5,299,442 shares (+96.5%) to their portfolio in Q2 2026, for an estimated $422,524,510
FULLER & THALER ASSET MANAGEMENT, INC. added 1,209,604 shares (+inf%) to their portfolio in Q2 2026, for an estimated $96,441,726
PRICE T ROWE ASSOCIATES INC /MD/ added 987,213 shares (+103.6%) to their portfolio in Q2 2026, for an estimated $78,710,492
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 674,033 shares (+inf%) to their portfolio in Q2 2026, for an estimated $53,740,651
JANE STREET GROUP, LLC removed 654,343 shares (-82.2%) from their portfolio in Q2 2026, for an estimated $52,170,767
AMERICAN CENTURY COMPANIES INC added 542,131 shares (+inf%) to their portfolio in Q2 2026, for an estimated $43,224,104
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 530,014 shares (-52.9%) from their portfolio in Q2 2026, for an estimated $42,258,016

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LQDA Price Targets

Multiple analysts have issued price targets for $LQDA recently. We have seen 5 analysts offer price targets for $LQDA in the last 6 months, with a median target of $75.0.

Here are some recent targets:

Jason Gerberry from B of A Securities set a target price of $79.0 on 06/29/2026
Julian Harrison from BTIG set a target price of $109.0 on 06/22/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $75.0 on 06/05/2026
Benjamin Burnett from Wells Fargo set a target price of $62.0 on 05/12/2026
Serge Belanger from Needham set a target price of $70.0 on 05/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.